Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Regorafenib

FDA-approved product (tablet, oral), marketed as Regorafenib, Stivarga.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Regorafenib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Colorectal adenocarcinoma
  • Colorectal cancer
  • Colorectal carcinoma
  • Colorectal neoplasm
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other protein kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA59.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli33.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Regorafenib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Regorafenib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Regorafenib Treatment Patterns and Survival Outcomes in Advanced Colorectal Cancer: A Real-world Study

    NCT04835324 · start 2020-10-01

    Registered record
    Registry ID
    NCT04835324
    Conditions
    Advanced Colorectal Cancer
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2020-10-01
    Completion
    2022-10-01
    Enrolment
    650

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Colorectal Cancer
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)

    NCT03555149 · start 2018-09-27

    Registered record
    Registry ID
    NCT03555149
    Conditions
    Colorectal Cancer
    Interventions
    Regorafenib; Atezolizumab; Imprime PGG; Bevacizumab; Isatuximab; Selicrelumab; Idasanutlin; AB928; LOAd703
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2018-09-27
    Completion
    2022-09-26
    Enrolment
    96

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    InterventionRegorafenib; Atezolizumab; Imprime PGG; Bevacizumab +5 more
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC

    NCT03347292 · start 2018-06-18

    Registered record
    Registry ID
    NCT03347292
    Conditions
    Carcinoma, Hepatocellular
    Interventions
    Regorafenib(Stivarga, BAY73-4506); Pembrolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-06-18
    Completion
    2022-09-06
    Enrolment
    58

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Hepatocellular
    InterventionRegorafenib(Stivarga, BAY73-4506); Pembrolizumab
    PhasePhase 1
    Registry statusCompleted

  • Study Maintenance Regorafenib vs Placebo, no Progression Patients After I Line Chemotherapy Metastatic Gastric Cancer

    NCT03627728 · start 2018-06-13

    Registered record
    Registry ID
    NCT03627728
    Conditions
    Gastric Cancer
    Interventions
    Regorafenib; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-06-13
    Completion
    2024-10-31
    Enrolment
    67

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastric Cancer
    InterventionRegorafenib; placebo
    PhasePhase 2
    Registry statusCompleted

  • To Determine the Safety of Regorafenib, Hydroxychloroquine, and Entinostat Metastatic Colorectal Cancer

    NCT03215264 · start 2017-10-02

    Registered record
    Registry ID
    NCT03215264
    Conditions
    Colorectal Cancer
    Interventions
    hydroxychloroquine; entinostat; regorafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-10-02
    Completion
    2020-06-01
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    Interventionhydroxychloroquine; entinostat; regorafenib
    PhasePhase 1
    Registry statusCompleted

  • Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)

    NCT03289273 · start 2017-09-13

    Registered record
    Registry ID
    NCT03289273
    Conditions
    Liver Neoplasms
    Interventions
    Regorafenib (Stivarga, BAY73-4506)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2017-09-13
    Completion
    2022-06-21
    Enrolment
    1,010

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Neoplasms
    InterventionRegorafenib (Stivarga, BAY73-4506)
    PhaseNot recorded
    Registry statusCompleted

  • A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer

    NCT02773524 · start 2016-11

    Registered record
    Registry ID
    NCT02773524
    Conditions
    Gastro-Oesophageal Cancer
    Interventions
    Regorafenib; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2016-11
    Completion
    2022-12
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastro-Oesophageal Cancer
    InterventionRegorafenib; Placebo
    PhasePhase 3
    Registry statusUnknown

  • Study Comparing Different Dose Approaches of Induction Treatment of Regorafenib in MCRC

    NCT02835924 · start 2016-07

    Registered record
    Registry ID
    NCT02835924
    Conditions
    Metastatic Colorectal Cancer
    Interventions
    Regorafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-07
    Completion
    2019-09
    Enrolment
    299

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Colorectal Cancer
    InterventionRegorafenib
    PhasePhase 2
    Registry statusCompleted

  • Efficacy of Ginseng for Patients on Regorafenib

    NCT02581059 · start 2016-04

    Registered record
    Registry ID
    NCT02581059
    Conditions
    Colorectal Cancer; Palliative Medicine; Supportive Care
    Interventions
    Regorafenib; Ginseng
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2016-04
    Completion
    2018-06-22
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer; Palliative Medicine; Supportive Care
    InterventionRegorafenib; Ginseng
    PhasePhase 2
    Registry statusTerminated

  • Effect of Pre-Transplant Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma Patients With Liver Transplantation

    NCT07418138 · start 2015-01-01

    Registered record
    Registry ID
    NCT07418138
    Conditions
    Liver Transplantation; Hepatocellular Carcinoma (HCC); Tyrosine Kinase Inhibitor; Survival Rate
    Interventions
    Medication history; Medication history
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-01-01
    Completion
    2024-12-31
    Enrolment
    484

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Transplantation; Hepatocellular Carcinoma (HCC); Tyrosine Kinase Inhibitor; Survival Rate
    InterventionMedication history; Medication history
    PhaseNot recorded
    Registry statusCompleted

  • Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer

    NCT02116894 · start 2014-08

    Registered record
    Registry ID
    NCT02116894
    Conditions
    Colorectal Cancer
    Interventions
    PF-03446962; Regorafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-08
    Completion
    2016-05
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    InterventionPF-03446962; Regorafenib
    PhasePhase 1
    Registry statusCompleted

  • Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma

    NCT02048722 · start 2014-06-13

    Registered record
    Registry ID
    NCT02048722
    Conditions
    Adult Angiosarcoma; Recurrent Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma
    Interventions
    regorafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-06-13
    Completion
    2021-10-12
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdult Angiosarcoma; Recurrent Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma
    Interventionregorafenib
    PhasePhase 2
    Registry statusCompleted

  • A Study of Regorafenib in Advanced Pancreatic Cancer Patients

    NCT02080260 · start 2014-06-06

    Registered record
    Registry ID
    NCT02080260
    Conditions
    Pancreatic Cancer
    Interventions
    regorafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-06-06
    Completion
    2017-06-28
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Cancer
    Interventionregorafenib
    PhasePhase 2
    Registry statusCompleted

  • A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer

    NCT02096354 · start 2014-05

    Registered record
    Registry ID
    NCT02096354
    Conditions
    Colorectal Neoplasms
    Interventions
    RRx-001; Regorafenib; Irinotecan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-05
    Completion
    2020-10-08
    Enrolment
    62

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Neoplasms
    InterventionRRx-001; Regorafenib; Irinotecan
    PhasePhase 2
    Registry statusCompleted

  • Regorafenib Versus Placebo to Treat Cholangiocarcinoma

    NCT02162914 · start 2014-03-14

    Registered record
    Registry ID
    NCT02162914
    Conditions
    Cholangiocarcinoma
    Interventions
    Regorafenib/active; Regorafenib/placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2014-03-14
    Completion
    2020-12
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCholangiocarcinoma
    InterventionRegorafenib/active; Regorafenib/placebo
    PhasePhase 2
    Registry statusUnknown